Evidence based medicine on the use of botulinum toxin for headache disorders
- 12 November 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Neural Transmission
- Vol. 115 (4), 647-651
- https://doi.org/10.1007/s00702-007-0832-3
Abstract
Botulinum toxin blocks the release of acetylcholine from motor nerve terminals and other cholinergic synapses. In animal studies botulinum toxin also reduces the release of neuropeptides involved in pain perception. The implications of these observations are not clear. Based on the personal experiences of headache therapists, botulinum toxin injections have been studied in patients with primary headaches, namely tension-type headache (TTH), chronic migraine (CM) and chronic daily headache (CDH). So far, the results of randomized, double-blind, placebo controlled trials on botulinum toxin in a total of 1117 patients with CDH, 1495 patients with CM, and 533 patients with TTH have been published. Botulinum toxin and placebo injections have been equally effective in these studies. In some of the studies, the magnitude of this effect was similar to that of established oral pharmacotherapy. This finding may help to explain the enthusiasm that followed the first open-label use of botulinum toxin in patients with headache. However, research is continuing to determine the efficacy of botulinum toxin in certain subgroups of patients with CM or CDH.Keywords
This publication has 52 references indexed in Scilit:
- A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Multiple Treatments of Botulinum Toxin Type A (BoNTA) for the Prophylaxis of Episodic Migraine HeadachesCephalalgia, 2007
- A Series of Three Sequential, Randomized, Controlled Studies of Repeated Treatments With Botulinum Toxin Type A for Migraine ProphylaxisThe Journal of Pain, 2006
- Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Tension-Type Headache: A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group StudyCephalalgia, 2006
- SV2 Is the Protein Receptor for Botulinum Neurotoxin AScience, 2006
- Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary studyThe Journal of Headache and Pain, 2003
- Effect of Botulinum Toxin A Injections in the Treatment of Chronic Tension‐type Headache: A Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2001
- The non-pfjptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigsLife Sciences, 1997